Drug Profile
Octreotide oral film - Aquestive Therapeutics
Alternative Names: AQST-305; Octreotide oral soluble film; Octreotide OSFLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Aquestive Therapeutics
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acromegaly; Malignant carcinoid syndrome
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in Acromegaly in Canada (Buccal, Film)
- 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in malignant carcinoid syndrome in Canada (Buccal, Film)
- 07 Jun 2021 Octreotide oral film is still in clinical trials for Acromegaly and malignant carcinoid syndrome in Canada (Aquestive Therapeutics pipeline, June 2021)